|
1) 一瀬白帝. 凝固13因子関連疾患の基礎と臨床—とくに後天性血友病13(出血性後天性凝固13因子欠乏症)について—. 日本小児血液学会雑誌. 2010; 24: 3-13
|
|
|
|
2) 一瀬白帝. 不育症と凝固XIII因子. 日本血栓止血学会誌. 2009; 20: 519-26
|
|
|
|
|
3) Koseki S, Souri M, Koga S, et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood. 2001; 97: 2667-72
|
|
|
|
|
4) Lauer P, Metzner HJ, Zettlmeissl G, et al. Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: hemostatic abnormalities in mutant mice and chara-cterization of the coagulation deficit. Thromb Haemost. 2002; 88: 967-74
|
|
|
|
|
|
5) Souri M, Koseki-Kuno S, Takeda N, et al. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol. 2008; 87: 60-8
|
|
|
|
|
|
6) Kasahara K, Souri M, Kaneda M, et al. Impaired clot retraction in factor XIII A subunit-deficient mice. Blood. 2010; 115: 1277-9
|
|
|
|
|
|
7) 一瀬白帝. 血栓の退縮—血栓の運命を決める血餅退縮反応のメカニズムとその意義—. 血管医学. 2011; 12: 59-73
|
|
|
|
|
|
8) Jayo A, Conde I, Lastres P, et al. Possible role for cellular FXIII in monocyte-derived dendritic cell motility. Eur J Cell Biol. 2009; 88: 423-31
|
|
|
|
|
|
9) Pawlinski R, Fernandes A, Kehrle B, et al. Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci U S A. 2002; 99: 15333-8
|
|
|
|
|
|
10) Suh TT, Holmbäck K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995; 9: 2020-33
|
|
|
|
|
|
11) Iwaki T, Sandoval-Cooper MJ, Paiva M, et al. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol. 2002; 160: 1021-34
|
|
|
|
|
|
12) Souri M, Koseki-Kuno S, Takeda N, et al. Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII. Thromb Haemost. 2008; 99: 401-8
|
|
|
|
|
|
13) Pawlinski R, Tencati M, Holscher T, et al. Role of cardiac myocyte tissue factor in heart hemostasis. J Thromb Haemost. 2007; 5: 1693-700
|
|
|
|
|
|
14) Nahrendorf M, Hu K, Frantz S, et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation. 2006; 113: 1196-202
|
|
|
|
|
|
15) Nahrendorf M, Aikawa E, Figueiredo JL, et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J. 2008; 29: 445-54
|
|
|
|
|
|
16) Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009; 325: 612-6
|
|
|
|
|
|
17) Dardik R, Krapp T, Rosenthal E, et al. Effect of FXIII on monocyte and fibroblast function. Cell Physiol Biochem. 2007; 19: 113-20
|
|
|
|
|
|
18) Dardik R, Leor J, Skutelsky E, et al. Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice. Thromb Haemost. 2006; 95: 546-50
|
|
|
|
|
|
19) Töröcsik D, Bárdos H, Nagy L, et al. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell Mol Life Sci. 2005; 62: 2132-9
|
|
|
|
|
|
20) Pabst MJ, Pabst KM, Handsman DB, et al. Proteome of monocyte priming by lipopoly-saccharide, including changes in interleukin1-beta and leukocyte elastase inhibitor. Proteome Sci. 2008; 6: 13
|
|
|
|
|
|
21) Chaitidis P, OʼDonnell V, Kuban RJ, et al. Gene expression alterations of human peripheral blood monocytes induced by medium-term treatment with the TH2-cytokines interleukin-4 and -13. Cytokine. 2005; 30: 366-77
|
|
|
|
|
|
22) Nishiura H, Tanase S, Tsujita K, et al. Maintenance of ribosomal protein S19 in plasma by complex formation with prothrombin. Eur J Haematol. 2011; 86: 436-41
|
|
|
|
|
|
23) Kawabata S, Muta T, Iwanaga S. Discovery of the lipopolysaccharide- and beta-1, 3-D-glucan-mediated proteolytic cascade and unique proteins in invertebrate immunity. J Biochem. 2010; 147: 611-8
|
|
|
|
|
|
24) Wang Z, Wilhelmsson C, Hyrsl P, et al. Pathogen entrapment by transglutaminase-a conserved early innate immune mechanism. PLoS Pathog. 2010; 6: e1000763
|
|
|
|
|
|
25) Loof TG, Mörgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood. 2011; 118: 2589-98
|
|
|
|
|
|
26) Ding JL, Li P, Ho B. The Sushi peptides: structural characterization and mode of action against Gram-negative bacteria. Cell Mol Life Sci. 2008; 65: 1202-19
|
|
|
|
|
|
27) Souri M, Kaetsu H, Ichinose A. Sushi domains in the B subunit of factor XIII responsible for oligomer assembly. Biochemistry. 2008; 47: 8656-64
|
|
|
|
|
|
28) Sárváry A, Szucs S, Balogh I, et al. Possible role of factor XIII subunit A in Fc gamma and complement receptor-mediated phagocytosis. Cell Immunol. 2004; 228: 81-90
|
|
|
|
|
|
29) Nahrendorf M, Sosnovik DE, Waterman P, et al. Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res. 2007; 100: 1218-25
|
|
|
|
|
|
30) Palumbo JS, Barney KA, Blevins EA, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008; 6: 812-9
|
|
|
|
|
|
31) Kitchens CS, Newcomb TF. Factor XIII. Medicine (Baltimore). 1979; 58: 413-29
|
|
|
|
|
|
32) Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev. 1993; 7: 229-42
|
|
|
|
|
|
33) Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia. 2008; 14: 1190-200
|
|
|
|
|
|
34) Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost. 2001; 86: 57-65
|
|
|
|
|
|
35) 一瀬白帝. II. 総括研究報告. 厚生労働科学研究費補助金(難治性疾患克服研究事業)｢後天性血友病XIII(13)の実態調査, 発症機序の解明と治療方法の開発に関する研究｣平成22年度総括・分担研究報告書. 2011. p.3-20
|
|
|
|
|
|
36) Seitz R, Duckert F, Lopaciuk S, et al. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. Semin Thromb Hemost. 1996; 22: 415-8
|
|
|
|
|
|
37) Ivaskevicius V, Biswas A, Loreth R, et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia. 2010; 16: 675-82
|
|
|
|
|
|
38) Gerlach R, Raabe A, Zimmermann M, et al. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol. 2000; 54: 260-4; discussion 264-5
|
|
|
|
|
|
39) Korte W. F. XIII in perioperative coagulation management. Best Pract Res Clin Anaesthesiol. 2010; 24: 85-93
|
|
|
|
|
|
40) 一瀬白帝. 後天性血友病XIII(13)(出血性後天性凝固第13因子欠乏症)とは？ 日本内科学会雑誌. 2010; 99: 1934-43
|
|
|
|
|
|
41) Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost. 2011; 37: 382-8
|
|
|
|
|
|
42) Ichinose A, Souri M; Japanese collaborative research group on“Acquired haemorrha-philia due to factor XIII deficiency". As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost. 2011; 105: 925-7
|
|
|
|
|
|
43) Iwaki T, Tanaka Am Miyawaki Y, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost. 2011; 9: 1200-6
|
|
|
|
|